ISPOR BOARD OF DIRECTORS ELECTION 2015

Published Mar 4, 2015
Dear Colleagues: The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a member-driven organization led by a diverse Board of Directors and professional staff who work collaboratively to ensure the organization is strategically positioned and effectively serving its membership. As such, ISPOR members are encouraged to participate in the election for the 2015-2016 ISPOR Board of Directors and help shape the future of ISPOR. ABOUT THE CANDIDATES: The ISPOR Board of Directors consists of the Officers (President, President-Elect, Immediate Past President), and seven Directors. The Board term of office for the President is one year as President-Elect, one year as a President, and one year as a Past President. After an extensive review and deliberation of more than 60 nominees, the ISPOR Nominations Committee has recommended the following candidates for the 2015-16 Board election. (All ISPOR members are strongly encouraged to review the candidate backgrounds and vote in this election. To read the candidate's biographical summary and their ISPOR vision statement go to: Candidate biographical summaries & ISPOR vision statements.) President-elect Lou Garrison, PhD (USA) Maarten J. IJzerman, PhD (The Netherlands) Director (Position 1) Diego Rosselli, MD, MED, MHP (Colombia) Manuel Espinoza S., MD, MSc, PhD (Chile) Director (Position 2) Dana Goldman, PhD (USA) Todd Lee, PharmD, PhD (USA) Director (Position 3) Nancy Devlin, PhD (UK) Mitchell Higashi, PhD (USA) TO VOTE: Access the ballot clicking on the “VOTE NOW!” icon below. You will be directed to enter your ISPOR member email address and member ID. All ballots are verified and tabulated by an independent agency.

YOU MUST VOTE BY MAY 1, 2015

Sincerely, William H. Crown, PhD 2014-2015 Board of Directors Nominations Committee Chair & 2014-2015 Past-President Vote Now!

Related Stories

Promoting Fairness in Funding Decisions

Jun 24, 2026

Value in Health announced the publication of a special themed section of research papers that offer new tools to help health policy makers weigh fairness alongside cost-effectiveness when deciding which treatments and programs to fund.

Listening to Patients in the Real World

Jun 23, 2026

Value in Health, the official journal of ISPOR announced today the publication of an ISPOR Good Practices Report outlining 9 areas to strengthen the robustness, transparency, and feasibility of real-world patient-reported outcomes studies.

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×